Development of APOBEC3B inhibitors: Recent advances and perspectives
Authors:
- 27 September 2025
- journal article
- review article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 165, 109042
Abstract
No abstract availableKeywords
Funding Information
- Qinglan Project of Jiangsu Province of China
- National Natural Science Foundation of China (82473774, 82073685)
This publication has 125 references indexed in Scilit:
- Viral whole genome sequencing reveals high variations in APOBEC3 editing between HPV risk categoriesJournal of Medical Virology, 2024
- The new direction of drug development: Degradation of undruggable targets through targeting chimera technologyMedicinal Research Reviews, 2023
- HPV‐16/18 E6‐induced APOBEC3B expression associates with proliferation of cervical cancer cells and hypomethylation of Cyclin D1Molecular Carcinogenesis, 2021
- Differential Inhibition of APOBEC3 DNA‐Mutator Isozymes by Fluoro‐ and Non‐Fluoro‐Substituted 2′‐Deoxyzebularine Embedded in Single‐Stranded DNAChemBioChem, 2019
- Strategies to diversify natural products for drug discoveryMedicinal Research Reviews, 2017
- Upregulation of pAKT(Ser473) expression in progression of HPV‐positive oropharyngeal squamous cell carcinomaHead & Neck, 2017
- Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinomaHepatology, 2007
- Inactivation of the SR Protein Splicing Factor ASF/SF2 Results in Genomic InstabilityCell, 2005
- An Anthropoid-Specific Locus of Orphan C to U RNA-Editing Enzymes on Chromosome 22Genomics, 2002
- Cytidine Deaminase. The 2·3 Å Crystal Structure of an Enzyme: Transition-state Analog ComplexJournal of Molecular Biology, 1994